DBV Technologies S.A. (EPA:DBV)

Market Cap	991.91M +1,149.7%
Revenue (ttm)	4.69M -56.0%
Net Income	-106.65M
EPS	-0.90
Shares Out	278.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,408,451
Average Volume	1,348,761
Open	3.590
Previous Close	3.530
Day's Range	3.505 - 3.760
52-Week Range	0.675 - 4.500
Beta	-0.22
RSI	45.17
Earnings Date	Mar 19, 2026

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company’s product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 117
• Stock Exchange: Euronext Paris
• Ticker Symbol: DBV

Financial Performance

In 2024, DBV Technologies's revenue was $4.15 million, a decrease of -73.61% compared to the previous year's $15.73 million. Losses were -$113.92 million, 56.6% more than in 2023.

Financial numbers in USD